Асосий контентга ўтиш
AkademIndex

Маҳсулотлар

Ишлаб чиқувчилар учун

AkademBaseЭкотизим учун очиқ API
← Ишга қайтиш

Ушбу иш иқтибос қилган ишлар

171 та иш

Иш: Exploring cellular immunotherapy platforms in multiple myeloma

  1. Nano based drug delivery systems: recent developments and future prospects

    Jayanta Kumar Patra, Gitishree Das, Leonardo Fernandes Fraceto +9

    Шарҳ мақола201811 иқтибос
    ABI

  2. Neoantigens: promising targets for cancer therapy

    Na Xie, Guobo Shen, Wei Gao +3

    Шарҳ мақола20236 иқтибос
    ABI

  3. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

    Nikhil C. Munshi, Larry D. Anderson, Nina Shah +25

    Мақола20215 иқтибос
    ABI

  4. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

    Noopur Raje, Jesús G. Berdeja, Yi Lin +20

    Мақола20194 иқтибос
    ABI

  5. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management

    S. Vincent Rajkumar

    Мақола20224 иқтибос
    ABI

  6. Bispecific T‐cell engagers for cancer immunotherapy

    Amelia M. Huehls, Tiffany A. Coupet, Charles L. Sentman

    Шарҳ мақола20143 иқтибос
    ABI

  7. Expanded natural killer cells augment the antimyeloma effect of daratumumab, bortezomib, and dexamethasone in a mouse model

    Jaya Lakshmi Thangaraj, Seo-Yeon Ahn, Sung‐Hoon Jung +12

    Мақола20213 иқтибос
    ABI

  8. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma

    Jianjun Chu, Youcai Deng, D.M. Benson +13

    Мақола20133 иқтибос
    ABI

  9. <i>In vivo</i> kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection

    Yan Zhang, Diana L. Wallace, Catherine M. de Lara +8

    Мақола20073 иқтибос
    ABI

  10. Clinical relevance of host immunity in breast cancer: from TILs to the clinic

    Peter Savas, Roberto Salgado, Carsten Denkert +4

    Шарҳ мақола20153 иқтибос
    ABI

  11. CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma.

    Joseph D. Malaer, Porunelloor A. Mathew

    Мақола20173 иқтибос
    ABI

  12. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Stephen J. Schuster, Michael Bishop, Constantine S. Tam +21

    Мақола20183 иқтибос
    ABI

  13. TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors

    Na Tang, Chen Cheng, Xingying Zhang +6

    Мақола20203 иқтибос
    ABI

  14. CAR-NK cells: A promising cellular immunotherapy for cancer

    Guozhu Xie, Han Dong, Yong Liang +3

    Шарҳ мақола20203 иқтибос
    ABI

  15. Bispecifics, trispecifics, and other novel immune treatments in myeloma

    Guido Lancman, Joshua Richter, Ajai Chari

    Шарҳ мақола20203 иқтибос
    ABI

  16. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy

    Ying Gong, Roel G. J. Klein Wolterink, Jianxiang Wang +2

    Шарҳ мақола20213 иқтибос
    ABI

  17. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial

    Ben Creelan, Chao Wang, Jamie K. Teer +23

    Мақола20213 иқтибос
    ABI

  18. Antibody drug conjugate: the “biological missile” for targeted cancer therapy

    Zhiwen Fu, Shijun Li, Sifei Han +2

    Шарҳ мақола20223 иқтибос
    ABI

  19. Focusing on NK cells and ADCC: A promising immunotherapy approach in targeted therapy for HER2-positive breast cancer

    Feifei Li, Sheng Liu

    Шарҳ мақола20223 иқтибос
    ABI

  20. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition

    Leonid Cherkassky, Aurore Morello, Jonathan Villena‐Vargas +5

    Мақола20162 иқтибос
    ABI

  21. CAR-T cells and combination therapies: What’s next in the immunotherapy revolution?

    María C. Ramello, Eric B. Haura, Daniel Abate‐Daga

    Мақола20172 иқтибос
    ABI

  22. The Next Generation of Cellular Immunotherapy: Chimeric Antigen Receptor-Natural Killer Cells

    Jake Moscarelli, David J. Zahavi, Rachael Maynard +1

    Шарҳ мақола20222 иқтибос
    ABI

  23. Anti-BCMA Dual Epitope-Binding CAR-Marrow Infiltrating Lymphocytes (MILs) Could Offer a Potent Innovative Immunotherapeutic Tool Against Multiple Myeloma

    Manh-Cuong Vo, Sunghoon Jung, Van‐Tan Nguyen +6

    Мақола20232 иқтибос
    ABI

  24. Harnessing Nanotechnology: Emerging Strategies for Multiple Myeloma Therapy

    Min Yang, Yu Chen, Li Zhu +5

    Шарҳ мақола20242 иқтибос
    ABI

  25. Ex vivo pulsed dendritic cell vaccination against cancer

    Yangzhuo Gu, Xing Zhao, Xiangrong Song

    Шарҳ мақола20202 иқтибос
    ABI